Inorganic nanocarriers for siRNA delivery for cancer treatments

RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method specifically uses therapeutic RNAs (TpRNAs) like small interfering RNAs (siRNAs) to regulate/silence the cancer-linked genes, thereby minimizing the distinct ac...

Full description

Saved in:
Bibliographic Details
Published inBiomedical materials (Bristol) Vol. 19; no. 2; pp. 22001 - 22027
Main Authors Kandasamy, Ganeshlenin, Maity, Dipak
Format Journal Article
LanguageEnglish
Published England IOP Publishing 01.03.2024
Subjects
Bcl-2 and VEGF
cancer treatment
chemotherapy
Drug Carriers
Drug Delivery Systems - methods
Humans
magnetic/metal/silica nanoparticles
Nanoparticles
Neoplasms - drug therapy
PD-L1
RNA, Small Interfering - genetics
siRNA
survivin
Vascular Endothelial Growth Factor A
cancer treatment
survivin
magnetic/metal/silica nanoparticles
Bcl-2 and VEGF
PD-L1
siRNA
chemotherapy
Online AccessGet full text

Cover

Abstract RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method specifically uses therapeutic RNAs (TpRNAs) like small interfering RNAs (siRNAs) to regulate/silence the cancer-linked genes, thereby minimizing the distinct activities of the cancer cells while aiding in their apoptosis. But, many complications arise during the transport/delivery of these TpRNAs that include poor systemic circulation, instability/degradation inside the body environment, no targeting capacity and also low cellular internalization. These difficulties can be overcome by using nanocarriers to deliver the TpRNAs inside the cancer cells. The following are the various categories of nanocarriers-viral vectors (e.g. lentivirus and adenovirus) and non-viral nanocarriers (self-assembling nanocarriers and inorganic nanocarriers). Viral vectors suffer from disadvantages like high immunogenicity compared to the non-viral nanocarriers. Among non-viral nanocarriers, inorganic nanocarriers gained significant attention as their inherent properties (like magnetic properties) can aid in the effective cellular delivery of the TpRNAs. Most of the prior reports have discussed about the delivery of TpRNAs through self-assembling nanocarriers; however very few have reviewed about their delivery using the inorganic nanoparticles. Therefore, in this review, we have mainly focussed on the delivery of TpRNAs-i.e. siRNA, especially programmed death ligand-1 (PD-L1), survivin, B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor and other siRNAs using the inorganic nanoparticles-mainly magnetic, metal and silica nanoparticles. Moreover, we have also discussed about the combined delivery of these TpRNAs along with chemotherapeutic drugs (mainly doxorubicin) and and therapeutic effectiveness.
AbstractList RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method specifically uses therapeutic RNAs (TpRNAs) like small interfering RNAs (siRNAs) to regulate/silence the cancer-linked genes, thereby minimizing the distinct activities of the cancer cells while aiding in their apoptosis. But, many complications arise during the transport/delivery of these TpRNAs that include poor systemic circulation, instability/degradation inside the body environment, no targeting capacity and also low cellular internalization. These difficulties can be overcome by using nanocarriers to deliver the TpRNAs inside the cancer cells. The following are the various categories of nanocarriers-viral vectors (e.g. lentivirus and adenovirus) and non-viral nanocarriers (self-assembling nanocarriers and inorganic nanocarriers). Viral vectors suffer from disadvantages like high immunogenicity compared to the non-viral nanocarriers. Among non-viral nanocarriers, inorganic nanocarriers gained significant attention as their inherent properties (like magnetic properties) can aid in the effective cellular delivery of the TpRNAs. Most of the prior reports have discussed about the delivery of TpRNAs through self-assembling nanocarriers; however very few have reviewed about their delivery using the inorganic nanoparticles. Therefore, in this review, we have mainly focussed on the delivery of TpRNAs-i.e. siRNA, especially programmed death ligand-1 (PD-L1), survivin, B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor and other siRNAs using the inorganic nanoparticles-mainly magnetic, metal and silica nanoparticles. Moreover, we have also discussed about the combined delivery of these TpRNAs along with chemotherapeutic drugs (mainly doxorubicin) and and therapeutic effectiveness.
RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method specifically uses therapeutic RNAs (TpRNAs) like small interfering RNAs (siRNAs) to regulate/silence the cancer-linked genes, thereby minimizing the distinct activities of the cancer cells while aiding in their apoptosis. But, many complications arise during the transport/delivery of these TpRNAs that include poor systemic circulation, instability/degradation inside the body environment, no targeting capacity and also low cellular internalization. These difficulties can be overcome by using nanocarriers to deliver the TpRNAs inside the cancer cells. The following are the various categories of nanocarriers-viral vectors (e.g. lentivirus and adenovirus) and non-viral nanocarriers (self-assembling nanocarriers and inorganic nanocarriers). Viral vectors suffer from disadvantages like high immunogenicity compared to the non-viral nanocarriers. Among non-viral nanocarriers, inorganic nanocarriers gained significant attention as their inherent properties (like magnetic properties) can aid in the effective cellular delivery of the TpRNAs. Most of the prior reports have discussed about the delivery of TpRNAs through self-assembling nanocarriers; however very few have reviewed about their delivery using the inorganic nanoparticles. Therefore, in this review, we have mainly focussed on the delivery of TpRNAs-i.e. siRNA, especially programmed death ligand-1 (PD-L1), survivin, B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor and other siRNAs using the inorganic nanoparticles-mainly magnetic, metal and silica nanoparticles. Moreover, we have also discussed about the combined delivery of these TpRNAs along with chemotherapeutic drugs (mainly doxorubicin) andin vitroandin vivotherapeutic effectiveness.
Abstract RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method specifically uses therapeutic RNAs (TpRNAs) like small interfering RNAs (siRNAs) to regulate/silence the cancer-linked genes, thereby minimizing the distinct activities of the cancer cells while aiding in their apoptosis. But, many complications arise during the transport/delivery of these TpRNAs that include poor systemic circulation, instability/degradation inside the body environment, no targeting capacity and also low cellular internalization. These difficulties can be overcome by using nanocarriers to deliver the TpRNAs inside the cancer cells. The following are the various categories of nanocarriers—viral vectors (e.g. lentivirus and adenovirus) and non-viral nanocarriers (self-assembling nanocarriers and inorganic nanocarriers). Viral vectors suffer from disadvantages like high immunogenicity compared to the non-viral nanocarriers. Among non-viral nanocarriers, inorganic nanocarriers gained significant attention as their inherent properties (like magnetic properties) can aid in the effective cellular delivery of the TpRNAs. Most of the prior reports have discussed about the delivery of TpRNAs through self-assembling nanocarriers; however very few have reviewed about their delivery using the inorganic nanoparticles. Therefore, in this review, we have mainly focussed on the delivery of TpRNAs—i.e. siRNA, especially programmed death ligand-1 (PD-L1), survivin, B-cell lymphoma-2 (Bcl-2), vascular endothelial growth factor and other siRNAs using the inorganic nanoparticles—mainly magnetic, metal and silica nanoparticles. Moreover, we have also discussed about the combined delivery of these TpRNAs along with chemotherapeutic drugs (mainly doxorubicin) and in vitro and in vivo therapeutic effectiveness.
Author Kandasamy, Ganeshlenin
Maity, Dipak
Author_xml – sequence: 1
  givenname: Ganeshlenin
  orcidid: 0000-0002-6849-6538
  surname: Kandasamy
  fullname: Kandasamy, Ganeshlenin
  organization: School of Electrical and Communication, Vel Tech Rangarajan Dr. Sagunthala R&D Institute of Science and Technology, Avadi Department of Biomedical Engineering, Chennai, India
– sequence: 2
  givenname: Dipak
  orcidid: 0000-0001-9792-0281
  surname: Maity
  fullname: Maity, Dipak
  organization: Texas A&M University Department of Environmental and Occupational Health, School of Public Health, College Station, TX 77843, United States of America
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38181441$$D View this record in MEDLINE/PubMed
BookMark eNp9kM9LwzAUx4NM3A-9e5Le9GBd0iRtc5Ix_DEYCrKDt5ClL9LRJjNphf33dnbuJJ7e4_H5fuF9xmhgnQWELgm-IzjPpyRjeZxi_j5VBVkrc4JGx9PguDMyROMQNhhzwak4Q0Oak5wwRkbofmGd_1C21JFV1mnlfQk-RMb5KJRvL7OogKr8Ar_7OWllNfio8aCaGmwTztGpUVWAi8OcoNXjw2r-HC9fnxbz2TLWNKVNzARL80RnmRHCMAYABSiOiQFa0FR302gqiDJJwVJhBMvyLFWacs0ZBaATdNPXbr37bCE0si6DhqpSFlwbZCII51mScN6huEe1dyF4MHLry1r5nSRY7q3JvRa5VyR7a13k6tDermsojoFfTR1w2wOl28qNa73tfv2v7_oPfF3XkgiZSJwkGBO5LQz9BmCPhqk
CODEN BMBUCS
Cites_doi 10.3390/ijms24043375
10.1016/j.ejphar.2021.174178
10.1126/sciadv.abc7031
10.2217/nnm.14.169
10.1016/j.ijpharm.2019.118572
10.1016/j.ijpharm.2013.08.079
10.2147/IJN.S155537
10.1021/acs.molpharmaceut.9b00189
10.1021/acs.jpcc.6b06759
10.2147/IJN.S85095
10.1155/2016/5497136
10.1098/rsta.2009.0273
10.1002/psc.2649
10.1021/acs.bioconjchem.3c00205
10.1016/j.ajps.2017.07.008
10.1016/j.biomaterials.2016.01.068
10.3390/molecules21121715
10.1016/j.molliq.2018.11.108
10.1007/s13346-022-01237-z
10.1002/wnan.1322
10.1039/C3CS60273G
10.3390/pharmaceutics12070630
10.1016/j.ijpharm.2015.10.058
10.2147/IJN.S78774
10.1039/C5TB02326B
10.1016/j.tips.2020.08.004
10.1021/acs.molpharmaceut.8b00810
10.1002/adma.201905823
10.3390/ph15050575
10.3390/v12090924
10.3390/nano11051084
10.1177/0885328219886953
10.3390/ijms19082230
10.1007/978-3-662-59596-1
10.3390/ijms12063705
10.1088/1361-6528/ab3f17
10.3978/j.issn.2218-676X.2013.07.02
10.1186/s12951-020-00759-3
10.1038/s41392-020-0207-x
10.1016/S1470-2045(13)70173-6
10.1016/j.nantod.2015.06.008
10.2147/IJN.S32900
10.1016/j.bcp.2021.114432
10.1016/j.bbagen.2021.129938
10.3791/58660
10.1002/jmri.24691
10.3390/nano5041906
10.1016/j.mtbio.2022.100220
10.1016/j.biomaterials.2010.09.039
10.1016/j.actbio.2019.02.031
10.1016/j.apsb.2020.10.005
10.1177/0960327116646618
10.3390/pharmaceutics13071009
10.1021/am5080453
10.3791/58814
10.1016/B978-0-12-820016-2.00005-7
10.1016/j.cej.2021.131120
10.1016/j.ejpb.2018.07.024
10.3390/pharmaceutics14112537
10.1016/j.apsb.2021.08.009
10.1039/c1cc15408g
10.1039/C7TB00382J
10.1208/s12248-010-9210-4
10.1002/cmmi.265
10.1002/smll.200900621
10.1007/978-3-211-73574-9_7
10.1016/j.molstruc.2020.128599
10.3390/molecules25112692
10.3390/nano9040511
10.2147/IJN.S137245
10.1021/acsptsci.2c00110
10.1016/j.biomaterials.2014.09.003
10.1007/s13758-011-0009-3
10.1039/C9TB00546C
10.1371/journal.pone.0092924
10.1021/mp9001393
10.1016/j.micromeso.2016.08.038
10.1016/j.colsurfb.2022.113002
10.1002/adfm.202005400
10.3390/pharmaceutics11110615
10.1021/la3044158
10.1016/j.addr.2023.115052
10.1016/j.biopha.2018.11.122
10.1007/s41061-020-00302-w
10.4314/tjpr.v13i7.23
10.1016/j.cej.2021.130746
10.1016/j.msec.2019.02.026
10.1016/j.addr.2020.07.022
10.1021/acs.accounts.9b00101
10.22037/ijpr.2021.115099.15219
10.1088/0957-4484/21/10/105105
10.1016/j.cis.2019.01.003
10.1002/chem.201702835
10.2478/raon-2022-0002
10.2174/1568026616666160715163346
10.3389/fchem.2020.00602
10.7150/thno.38069
10.1039/c1cc11760b
10.3390/nano7050110
10.3390/ph13100294
10.3390/magnetochemistry6010011
10.1016/j.semcancer.2019.12.016
10.7150/thno.37586
10.1016/j.msec.2021.112199
10.1039/C5NR00211G
10.1038/s41587-021-00838-2
10.1021/acs.bioconjchem.7b00483
10.1016/j.biomaterials.2011.08.068
10.2217/nnm.14.171
10.1021/acsami.1c04081
10.1016/j.biomaterials.2014.07.049
10.4103/0975-7406.72127
10.3390/pharmaceutics13030394
10.3390/nano9020191
10.1002/wnan.1449
10.1016/j.ijpharm.2021.120291
10.1016/j.nano.2013.09.011
10.1002/ddr.21571
10.1016/j.biopha.2019.109561
10.1002/jcp.28655
10.2147/IJN.S218085
10.1021/acsami.6b02963
10.1039/C6CP02094A
10.1016/j.jcis.2017.12.064
10.3109/1061186X.2011.622404
10.1021/acs.chemrev.8b00733
10.2147/IJN.S140772
10.5772/13059
10.3390/ijms22137055
10.1016/j.jare.2018.06.005
10.1016/j.matt.2020.09.020
10.2147/IJN.S117495
10.3109/1061186X.2015.1070857
10.1016/j.addr.2019.05.004
10.1016/j.molliq.2019.111549
10.1007/978-3-030-29768-8_12
10.1016/j.actbio.2019.08.046
10.1016/j.jconrel.2019.10.007
10.1016/j.trsl.2019.07.006
10.1021/acsami.8b02398
10.3390/cancers3033279
10.1016/j.colsurfb.2016.05.076
10.1016/j.jcis.2017.10.001
10.1016/j.msec.2019.110555
10.1016/j.addr.2020.06.020
10.1039/C9QM00666D
10.1021/acs.chemmater.9b01798
10.1016/j.apsusc.2019.04.059
10.2174/1570159X19666210402104054
10.3390/ijms20215491
10.2217/nnm-2018-0170
10.3390/nano12101692
10.1039/C5RA18464A
10.1016/j.ejpb.2020.08.026
10.1016/j.jpba.2017.04.025
10.1039/c2cc35515a
10.1002/adfm.201902634
10.1016/j.ajps.2020.02.004
10.1021/acsomega.8b00207
10.1016/j.biomaterials.2017.07.024
10.1016/j.ejpb.2018.04.018
ContentType Journal Article
Copyright 2024 IOP Publishing Ltd
2024 IOP Publishing Ltd.
Copyright_xml – notice: 2024 IOP Publishing Ltd
– notice: 2024 IOP Publishing Ltd.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1088/1748-605X/ad1baf
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
EISSN 1748-605X
ExternalDocumentID 10_1088_1748_605X_ad1baf
38181441
bmmad1baf
Genre Journal Article
Review
GroupedDBID ---
1JI
23N
4.4
53G
5B3
5GY
5VS
5ZH
7.M
7.Q
AAGCD
AAJIO
AAJKP
AATNI
ABHWH
ABJNI
ABQJV
ABVAM
ACAFW
ACGFS
ACHIP
AEFHF
AENEX
AFYNE
AKPSB
ALMA_UNASSIGNED_HOLDINGS
AOAED
ASPBG
ATQHT
AVWKF
AZFZN
CEBXE
CJUJL
CRLBU
CS3
DU5
EBS
EDWGO
EMSAF
EPQRW
EQZZN
F5P
HAK
IJHAN
IOP
IZVLO
KOT
LAP
N5L
N9A
P2P
PJBAE
RIN
RNS
RO9
ROL
RPA
S3P
SY9
UCJ
W28
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c363t-494682c77f99f44eeedea501fe3d36c1fefc391af2d469f947876ac35c543ee3
IEDL.DBID IOP
ISSN 1748-6041
IngestDate Fri Jun 28 08:14:25 EDT 2024
Fri Aug 23 01:12:41 EDT 2024
Sat Nov 02 12:26:11 EDT 2024
Sun Aug 18 15:30:26 EDT 2024
Tue Aug 20 22:16:42 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords cancer treatment
survivin
magnetic/metal/silica nanoparticles
Bcl-2 and VEGF
PD-L1
siRNA
chemotherapy
Language English
License This article is available under the terms of the IOP-Standard License.
2024 IOP Publishing Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c363t-494682c77f99f44eeedea501fe3d36c1fefc391af2d469f947876ac35c543ee3
Notes BMM-105717.R1
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ORCID 0000-0002-6849-6538
0000-0001-9792-0281
OpenAccessLink https://doi.org/10.1088/1748-605x/ad1baf
PMID 38181441
PQID 2915572255
PQPubID 23479
PageCount 27
ParticipantIDs proquest_miscellaneous_2915572255
crossref_primary_10_1088_1748_605X_ad1baf
iop_journals_10_1088_1748_605X_ad1baf
pubmed_primary_38181441
PublicationCentury 2000
PublicationDate 2024-03-01
PublicationDateYYYYMMDD 2024-03-01
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biomedical materials (Bristol)
PublicationTitleAbbrev BMM
PublicationTitleAlternate Biomed. Mater
PublicationYear 2024
Publisher IOP Publishing
Publisher_xml – name: IOP Publishing
References Zuo (bmmad1bafbib143) 2017; 23
Santana-Armas (bmmad1bafbib28) 2021; 596
Wang (bmmad1bafbib120) 2016; 4
Guruprasath (bmmad1bafbib122) 2017; 142
You (bmmad1bafbib137) 2023; 13
Lu (bmmad1bafbib102) 2018; 13
Shen (bmmad1bafbib121) 2012; 7
Yang (bmmad1bafbib134) 2018; 13
Dammes (bmmad1bafbib13) 2020; 41
Kumar (bmmad1bafbib84) 2013; 2
Du (bmmad1bafbib153) 2019; 7
Kandasamy (bmmad1bafbib30) 2023; 221
Tong (bmmad1bafbib19) 2023; 24
Choi (bmmad1bafbib123) 2015; 7
Maurer (bmmad1bafbib138) 2021; 13
Riley (bmmad1bafbib75) 2017; 9
Cao (bmmad1bafbib65) 2017; 5
Zhou (bmmad1bafbib149) 2016; 120
Li (bmmad1bafbib73) 2015; 10
Guo (bmmad1bafbib155) 2022; 428
Maity (bmmad1bafbib48) 2019
Ranjbar (bmmad1bafbib106) 2023; 201
Avasthi (bmmad1bafbib54) 2020; 378
Kandasamy (bmmad1bafbib47) 2020
Kandasamy (bmmad1bafbib58) 2019; 275
Dong (bmmad1bafbib15) 2019; 144
Li (bmmad1bafbib89) 2011; 32
Guo (bmmad1bafbib78) 2017; 12
Liu (bmmad1bafbib88) 2019; 9
Luo (bmmad1bafbib109) 2017; 12
Gu (bmmad1bafbib128) 2015; 10
Luther (bmmad1bafbib31) 2020; 156
Sztandera (bmmad1bafbib79) 2019; 16
Selvarajan (bmmad1bafbib85) 2020; 8
Lee (bmmad1bafbib14) 2019; 313
Kandasamy (bmmad1bafbib9) 2015; 496
Nardecchia (bmmad1bafbib35) 2019; 9
Kami (bmmad1bafbib22) 2011; 12
Maity (bmmad1bafbib53) 2012; 48
Brenner (bmmad1bafbib24) 2013; 14
Cole (bmmad1bafbib83) 2015; 10
Zhang (bmmad1bafbib16) 2021; 189
(bmmad1bafbib4) 2021; 39
Labala (bmmad1bafbib145) 2016; 146
Mainini (bmmad1bafbib26) 2020; 25
Guisasola (bmmad1bafbib34) 2018; 10
Almeida (bmmad1bafbib70) 2014; 10
Wang (bmmad1bafbib104) 2010; 12
Liu (bmmad1bafbib161) 2022; 5
Mi (bmmad1bafbib37) 2020; 10
Liu (bmmad1bafbib111) 2019; 99
Revia (bmmad1bafbib80) 2019; 52
Sun (bmmad1bafbib130) 2021; 20
Hu (bmmad1bafbib11) 2020; 5
Wang (bmmad1bafbib72) 2020; 30
Han (bmmad1bafbib32) 2020; 3
Narasipura (bmmad1bafbib105) 2023; 34
Kandasamy (bmmad1bafbib10) 2021; 127
Said (bmmad1bafbib38) 2019; 31
Kamalzare (bmmad1bafbib95) 2019; 234
Pawar (bmmad1bafbib2) 2019; 110
Xing (bmmad1bafbib60) 2011; 47
Biju (bmmad1bafbib97) 2014; 43
Zhang (bmmad1bafbib144) 2021; 426
Peng (bmmad1bafbib154) 2014; 9
de Brito E Cunha (bmmad1bafbib160) 2022; 15
Yamada (bmmad1bafbib71) 2015; 7
Moreira (bmmad1bafbib94) 2016; 236
Dalmina (bmmad1bafbib124) 2019; 99
S-h (bmmad1bafbib90) 2011; 47
Wang (bmmad1bafbib146) 2020; 4
Mody (bmmad1bafbib68) 2010; 2
Kandasamy (bmmad1bafbib57) 2018; 3
Chen (bmmad1bafbib150) 2009; 5
Kostevšek (bmmad1bafbib50) 2020; 6
Cabane (bmmad1bafbib41) 2012; 7
Aslan (bmmad1bafbib81) 2020; 1219
Galdiero (bmmad1bafbib21) 2014; 20
Cai (bmmad1bafbib63) 2019; 14
Hattab (bmmad1bafbib18) 2021; 13
Casula (bmmad1bafbib62) 2016; 18
Li (bmmad1bafbib151) 2016; 8
Zhou (bmmad1bafbib6) 2020; 6
Pham (bmmad1bafbib36) 2020; 12
Peng (bmmad1bafbib100) 2020; 15
Lin (bmmad1bafbib136) 2014; 35
Guthi (bmmad1bafbib42) 2010; 7
Kirui (bmmad1bafbib82) 2010; 21
Ding (bmmad1bafbib91) 2016; 21
Chen (bmmad1bafbib127) 2014; 35
Yang (bmmad1bafbib152) 2021; 19
Jin (bmmad1bafbib114) 2019; 11
Sajid (bmmad1bafbib17) 2020; 13
Cao (bmmad1bafbib131) 2022; 12
Sobańska (bmmad1bafbib64) 2021; 11
Wang (bmmad1bafbib133) 2018; 19
Liu (bmmad1bafbib129) 2015; 10
Zhang (bmmad1bafbib113) 2022; 13
Amiri (bmmad1bafbib3) 2021; 19
Yao (bmmad1bafbib76) 2016; 2016
Amiri (bmmad1bafbib45) 2019; 265
Labatut (bmmad1bafbib44) 2018; 128
Kandasamy (bmmad1bafbib46) 2019; 30
Jia (bmmad1bafbib96) 2019; 2019
Song (bmmad1bafbib86) 2016; 12
Zoulikha (bmmad1bafbib7) 2022; 12
Eljack (bmmad1bafbib147) 2022; 14
Navyatha (bmmad1bafbib74) 2019; 14
Cristofolini (bmmad1bafbib139) 2020; 109
Bae (bmmad1bafbib126) 2011; 32
Panday (bmmad1bafbib132) 2020; 34
Carlos (bmmad1bafbib66) 2011
Rajendrakumar (bmmad1bafbib148) 2019; 16
Geraldes (bmmad1bafbib67) 2009; 4
Wang (bmmad1bafbib117) 2015; 5
Zhang (bmmad1bafbib61) 2015; 7
Wu (bmmad1bafbib112) 2017; 7
Taratula (bmmad1bafbib158) 2011; 19
Hossen (bmmad1bafbib107) 2019; 15
Bruniaux (bmmad1bafbib118) 2019; 569
Manzano (bmmad1bafbib93) 2020; 30
Maity (bmmad1bafbib49) 2019
Lee (bmmad1bafbib159) 2016; 86
Kashapov (bmmad1bafbib39) 2021; 22
Yonezawa (bmmad1bafbib25) 2020; 154–155
Liu (bmmad1bafbib110) 2019; 9
Arami (bmmad1bafbib116) 2017; 142
Khan (bmmad1bafbib69) 2014; 13
Charbe (bmmad1bafbib43) 2020; 10
Arami (bmmad1bafbib115) 2017; 36
Babaei (bmmad1bafbib156) 2020; 156
Di Pietro (bmmad1bafbib77) 2016; 16
Wacker (bmmad1bafbib98) 2013; 457
Preiss (bmmad1bafbib142) 2017; 28
Alshaer (bmmad1bafbib12) 2021; 905
Peng (bmmad1bafbib135) 2021; 13
Afzal (bmmad1bafbib29) 2021; 69
Kandasamy (bmmad1bafbib55) 2019; 293
Kandasamy (bmmad1bafbib56) 2018; 514
Sperling (bmmad1bafbib99) 2010; 368
Bezeljak (bmmad1bafbib23) 2022; 56
Faruqu (bmmad1bafbib101) 2018; 5
Dua (bmmad1bafbib8) 2019; 80
Heuer-Jungemann (bmmad1bafbib40) 2019; 119
Patil (bmmad1bafbib27) 2019; 20
Lundstrom (bmmad1bafbib20) 2020; 12
Ding (bmmad1bafbib59) 2020; 32
Song (bmmad1bafbib157) 2020; 125
Martínez-Carmona (bmmad1bafbib87) 2015; 5
Conde (bmmad1bafbib108) 2015; 10
Kim (bmmad1bafbib33) 2013; 29
Li (bmmad1bafbib92) 2019; 89
Koutsilieri (bmmad1bafbib5) 2007
Vamvakidis (bmmad1bafbib52) 2018; 511
Ben Djemaa (bmmad1bafbib140) 2018; 131
Hou (bmmad1bafbib119) 2016; 24
H-k (bmmad1bafbib141) 2019; 483
Souza (bmmad1bafbib125) 2021; 1865
Subhan (bmmad1bafbib103) 2019; 214
Arruebo (bmmad1bafbib1) 2011; 3
Bashir (bmmad1bafbib51) 2015; 41
References_xml – volume: 24
  start-page: 3375
  year: 2023
  ident: bmmad1bafbib19
  article-title: Research status and prospect of non-viral vectors based on siRNA: a review
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms24043375
  contributor:
    fullname: Tong
– volume: 905
  year: 2021
  ident: bmmad1bafbib12
  article-title: siRNA: mechanism of action, challenges, and therapeutic approaches
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2021.174178
  contributor:
    fullname: Alshaer
– volume: 6
  start-page: eabc7031
  year: 2020
  ident: bmmad1bafbib6
  article-title: Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abc7031
  contributor:
    fullname: Zhou
– volume: 10
  start-page: 299
  year: 2015
  ident: bmmad1bafbib73
  article-title: Gold nanoparticles for photoacoustic imaging
  publication-title: Nanomedicine
  doi: 10.2217/nnm.14.169
  contributor:
    fullname: Li
– volume: 569
  year: 2019
  ident: bmmad1bafbib118
  article-title: Magnetic nanocarriers for the specific delivery of siRNA: contribution of breast cancer cells active targeting for down-regulation efficiency
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2019.118572
  contributor:
    fullname: Bruniaux
– volume: 457
  start-page: 50
  year: 2013
  ident: bmmad1bafbib98
  article-title: Nanocarriers for intravenous injection—the long hard road to the market
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2013.08.079
  contributor:
    fullname: Wacker
– volume: 13
  start-page: 1851
  year: 2018
  ident: bmmad1bafbib134
  article-title: Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S155537
  contributor:
    fullname: Yang
– volume: 16
  start-page: 2226
  year: 2019
  ident: bmmad1bafbib148
  article-title: Hyaluronan-stabilized redox-sensitive nanoassembly for chemo-gene therapy and dual T1/T2 MR imaging in drug-resistant breast cancer cells
  publication-title: Mol. Pharm.
  doi: 10.1021/acs.molpharmaceut.9b00189
  contributor:
    fullname: Rajendrakumar
– volume: 120
  start-page: 22375
  year: 2016
  ident: bmmad1bafbib149
  article-title: Dual-responsive mesoporous silica nanoparticles mediated codelivery of doxorubicin and Bcl-2 SiRNA for targeted treatment of breast cancer
  publication-title: J. Phys. Chem. C
  doi: 10.1021/acs.jpcc.6b06759
  contributor:
    fullname: Zhou
– volume: 10
  start-page: 4279
  year: 2015
  ident: bmmad1bafbib129
  article-title: Polyetherimide-grafted Fe3O4@SiO2 nanoparticles as theranostic agents for simultaneous VEGF siRNA delivery and magnetic resonance cell imaging
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S85095
  contributor:
    fullname: Liu
– volume: 2016
  start-page: 1
  year: 2016
  ident: bmmad1bafbib76
  article-title: Gold nanoparticle mediated phototherapy for cancer
  publication-title: J. Nanomater.
  doi: 10.1155/2016/5497136
  contributor:
    fullname: Yao
– volume: 368
  start-page: 1333
  year: 2010
  ident: bmmad1bafbib99
  article-title: Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles
  publication-title: Phil. Trans. R. Soc. A
  doi: 10.1098/rsta.2009.0273
  contributor:
    fullname: Sperling
– volume: 20
  start-page: 468
  year: 2014
  ident: bmmad1bafbib21
  article-title: Exploitation of viral properties for intracellular delivery
  publication-title: J. Pept. Sci.
  doi: 10.1002/psc.2649
  contributor:
    fullname: Galdiero
– volume: 34
  start-page: 1177
  year: 2023
  ident: bmmad1bafbib105
  article-title: Ongoing clinical trials of nonviral siRNA therapeutics
  publication-title: Bioconjug. Chem.
  doi: 10.1021/acs.bioconjchem.3c00205
  contributor:
    fullname: Narasipura
– volume: 13
  start-page: 1
  year: 2018
  ident: bmmad1bafbib102
  article-title: Exosome-based small RNA delivery: progress and prospects
  publication-title: Asian J. Pharm. Sci.
  doi: 10.1016/j.ajps.2017.07.008
  contributor:
    fullname: Lu
– volume: 86
  start-page: 92
  year: 2016
  ident: bmmad1bafbib159
  article-title: A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2016.01.068
  contributor:
    fullname: Lee
– volume: 21
  start-page: 1715
  year: 2016
  ident: bmmad1bafbib91
  article-title: Recent advances in stimuli-responsive release function drug delivery systems for tumor treatment
  publication-title: Molecules
  doi: 10.3390/molecules21121715
  contributor:
    fullname: Ding
– volume: 275
  start-page: 699
  year: 2019
  ident: bmmad1bafbib58
  article-title: One-pot synthesis of hydrophilic flower-shaped iron oxide nanoclusters (IONCs) based ferrofluids for magnetic fluid hyperthermia applications
  publication-title: J. Mol. Liq.
  doi: 10.1016/j.molliq.2018.11.108
  contributor:
    fullname: Kandasamy
– volume: 13
  start-page: 782
  year: 2023
  ident: bmmad1bafbib137
  article-title: Magnetically responsive nanoplatform targeting circRNA circ_0058051 inhibits hepatocellular carcinoma progression
  publication-title: Drug Deliv. Trans. Res.
  doi: 10.1007/s13346-022-01237-z
  contributor:
    fullname: You
– volume: 7
  start-page: 428
  year: 2015
  ident: bmmad1bafbib71
  article-title: Therapeutic gold, silver, and platinum nanoparticles
  publication-title: Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnology
  doi: 10.1002/wnan.1322
  contributor:
    fullname: Yamada
– volume: 43
  start-page: 744
  year: 2014
  ident: bmmad1bafbib97
  article-title: Chemical modifications and bioconjugate reactions of nanomaterials for sensing, imaging, drug delivery and therapy
  publication-title: Chem. Soc. Rev.
  doi: 10.1039/C3CS60273G
  contributor:
    fullname: Biju
– volume: 12
  start-page: 630
  year: 2020
  ident: bmmad1bafbib36
  article-title: Stimuli-responsive nanomaterials for application in antitumor therapy and drug delivery
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics12070630
  contributor:
    fullname: Pham
– volume: 496
  start-page: 191
  year: 2015
  ident: bmmad1bafbib9
  article-title: Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2015.10.058
  contributor:
    fullname: Kandasamy
– volume: 10
  start-page: 2579
  year: 2015
  ident: bmmad1bafbib128
  article-title: Highly effective antiangiogenesis via magnetic mesoporous silica-based siRNA vehicle targeting the VEGF gene for orthotopic ovarian cancer therapy
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S78774
  contributor:
    fullname: Gu
– volume: 4
  start-page: 2519
  year: 2016
  ident: bmmad1bafbib120
  article-title: A novel multifunctional biomimetic Au@BSA nanocarrier as a potential siRNA theranostic nanoplatform
  publication-title: J. Mater. Chem. B
  doi: 10.1039/C5TB02326B
  contributor:
    fullname: Wang
– volume: 41
  start-page: 755
  year: 2020
  ident: bmmad1bafbib13
  article-title: Paving the road for RNA therapeutics
  publication-title: Trends Pharmacol. Sci.
  doi: 10.1016/j.tips.2020.08.004
  contributor:
    fullname: Dammes
– volume: 16
  start-page: 1
  year: 2019
  ident: bmmad1bafbib79
  article-title: Gold nanoparticles in cancer treatment
  publication-title: Mol. Pharm.
  doi: 10.1021/acs.molpharmaceut.8b00810
  contributor:
    fullname: Sztandera
– volume: 32
  year: 2020
  ident: bmmad1bafbib59
  article-title: Manganese oxide nanomaterials: synthesis, properties, and theranostic applications
  publication-title: Adv. Mater.
  doi: 10.1002/adma.201905823
  contributor:
    fullname: Ding
– volume: 15
  start-page: 1
  year: 2022
  ident: bmmad1bafbib160
  article-title: Biotechnological evolution of siRNA molecules: from bench tool to the refined drug
  publication-title: Pharmaceuticals
  doi: 10.3390/ph15050575
  contributor:
    fullname: de Brito E Cunha
– volume: 12
  start-page: 924
  year: 2020
  ident: bmmad1bafbib20
  article-title: Viral vectors applied for RNAi-based antiviral therapy
  publication-title: Viruses
  doi: 10.3390/v12090924
  contributor:
    fullname: Lundstrom
– volume: 11
  start-page: 1084
  year: 2021
  ident: bmmad1bafbib64
  article-title: Applications and biological activity of nanoparticles of manganese and manganese oxides in in vitro and in vivo models
  publication-title: Nanomaterials
  doi: 10.3390/nano11051084
  contributor:
    fullname: Sobańska
– volume: 34
  start-page: 952
  year: 2020
  ident: bmmad1bafbib132
  article-title: Functionally modified magnetic nanoparticles for effective siRNA delivery to prostate cancer cells in vitro
  publication-title: J. Biomater. Appl.
  doi: 10.1177/0885328219886953
  contributor:
    fullname: Panday
– volume: 19
  start-page: 2230
  year: 2018
  ident: bmmad1bafbib133
  article-title: PEI-coated Fe3O4 nanoparticles enable efficient delivery of therapeutic siRNA targeting REST into glioblastoma cells
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms19082230
  contributor:
    fullname: Wang
– start-page: 299
  year: 2019
  ident: bmmad1bafbib49
  doi: 10.1007/978-3-662-59596-1
  contributor:
    fullname: Maity
– volume: 12
  start-page: 3705
  year: 2011
  ident: bmmad1bafbib22
  article-title: Application of magnetic nanoparticles to gene delivery
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms12063705
  contributor:
    fullname: Kami
– volume: 30
  year: 2019
  ident: bmmad1bafbib46
  article-title: Recent advancements in manganite perovskites and spinel ferrite-based magnetic nanoparticles for biomedical theranostic applications
  publication-title: Nanotechnology
  doi: 10.1088/1361-6528/ab3f17
  contributor:
    fullname: Kandasamy
– volume: 2
  start-page: 1
  year: 2013
  ident: bmmad1bafbib84
  article-title: Third generation gold nanoplatform optimized for radiation therapy
  publication-title: Transl. Cancer Res.
  doi: 10.3978/j.issn.2218-676X.2013.07.02
  contributor:
    fullname: Kumar
– volume: 19
  start-page: 54
  year: 2021
  ident: bmmad1bafbib152
  article-title: Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy
  publication-title: J. Nanobiotechnology
  doi: 10.1186/s12951-020-00759-3
  contributor:
    fullname: Yang
– volume: 5
  start-page: 101
  year: 2020
  ident: bmmad1bafbib11
  article-title: Therapeutic siRNA: state of the art
  publication-title: Signal Transduct. Target. Ther.
  doi: 10.1038/s41392-020-0207-x
  contributor:
    fullname: Hu
– volume: 14
  start-page: e447
  year: 2013
  ident: bmmad1bafbib24
  article-title: Is cancer gene therapy an empty suit?
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(13)70173-6
  contributor:
    fullname: Brenner
– volume: 10
  start-page: 421
  year: 2015
  ident: bmmad1bafbib108
  article-title: 15 years on siRNA delivery: beyond the state-of-the-art on inorganic nanoparticles for RNAi therapeutics
  publication-title: Nano Today
  doi: 10.1016/j.nantod.2015.06.008
  contributor:
    fullname: Conde
– volume: 7
  start-page: 3319
  year: 2012
  ident: bmmad1bafbib121
  article-title: An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S32900
  contributor:
    fullname: Shen
– volume: 189
  year: 2021
  ident: bmmad1bafbib16
  article-title: The growth of siRNA-based therapeutics: updated clinical studies
  publication-title: Biochem. Pharmacol.
  doi: 10.1016/j.bcp.2021.114432
  contributor:
    fullname: Zhang
– volume: 1865
  year: 2021
  ident: bmmad1bafbib125
  article-title: Short interfering RNA delivered by a hybrid nanoparticle targeting VEGF: biodistribution and anti-tumor effect
  publication-title: Biochim. Biophys. Acta Gen. Subj.
  doi: 10.1016/j.bbagen.2021.129938
  contributor:
    fullname: Souza
– volume: 2019
  start-page: 1
  year: 2019
  ident: bmmad1bafbib96
  article-title: Polyethyleneimine-coated iron oxide nanoparticles as a vehicle for the delivery of small interfering RNA to macrophages in vitro and in vivo
  publication-title: J. Vis. Exp.
  doi: 10.3791/58660
  contributor:
    fullname: Jia
– volume: 41
  start-page: 884
  year: 2015
  ident: bmmad1bafbib51
  article-title: Emerging applications for ferumoxytol as a contrast agent in MRI
  publication-title: J. Magn. Reson. Imaging
  doi: 10.1002/jmri.24691
  contributor:
    fullname: Bashir
– volume: 5
  start-page: 1906
  year: 2015
  ident: bmmad1bafbib87
  article-title: Smart mesoporous nanomaterials for antitumor therapy
  publication-title: Nanomaterials
  doi: 10.3390/nano5041906
  contributor:
    fullname: Martínez-Carmona
– volume: 13
  year: 2022
  ident: bmmad1bafbib113
  article-title: Enhanced fluorescence/magnetic resonance dual imaging and gene therapy of liver cancer using cationized amylose nanoprobe
  publication-title: Mater. Today Bio.
  doi: 10.1016/j.mtbio.2022.100220
  contributor:
    fullname: Zhang
– volume: 32
  start-page: 176
  year: 2011
  ident: bmmad1bafbib126
  article-title: Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2010.09.039
  contributor:
    fullname: Bae
– volume: 89
  start-page: 1
  year: 2019
  ident: bmmad1bafbib92
  article-title: Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer
  publication-title: Acta Biomater.
  doi: 10.1016/j.actbio.2019.02.031
  contributor:
    fullname: Li
– volume: 10
  start-page: 2075
  year: 2020
  ident: bmmad1bafbib43
  article-title: Small interfering RNA for cancer treatment: overcoming hurdles in delivery
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2020.10.005
  contributor:
    fullname: Charbe
– volume: 36
  start-page: 227
  year: 2017
  ident: bmmad1bafbib115
  article-title: Synthesis and characterization of Fe3O4-PEG-LAC-chitosan-PEI nanoparticle as a survivin siRNA delivery system
  publication-title: Hum. Exp. Toxicol.
  doi: 10.1177/0960327116646618
  contributor:
    fullname: Arami
– volume: 13
  start-page: 1009
  year: 2021
  ident: bmmad1bafbib18
  article-title: Clinical advances of siRNA-based nanotherapeutics for cancer treatment
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13071009
  contributor:
    fullname: Hattab
– volume: 7
  start-page: 4650
  year: 2015
  ident: bmmad1bafbib61
  article-title: Manganese doped iron oxide theranostic nanoparticles for combined T 1 magnetic resonance imaging and photothermal therapy
  publication-title: ACS Appl. Mater. Interfaces
  doi: 10.1021/am5080453
  contributor:
    fullname: Zhang
– volume: 5
  year: 2018
  ident: bmmad1bafbib101
  article-title: Preparation of exosomes for siRNA delivery to cancer cells
  publication-title: J. Vis. Exp.
  doi: 10.3791/58814
  contributor:
    fullname: Faruqu
– start-page: 71
  year: 2020
  ident: bmmad1bafbib47
  doi: 10.1016/B978-0-12-820016-2.00005-7
  contributor:
    fullname: Kandasamy
– volume: 428
  year: 2022
  ident: bmmad1bafbib155
  article-title: Homotypic biomimetic coating synergizes chemo-photothermal combination therapy to treat breast cancer overcoming drug resistance
  publication-title: Chem. Eng. J.
  doi: 10.1016/j.cej.2021.131120
  contributor:
    fullname: Guo
– volume: 131
  start-page: 99
  year: 2018
  ident: bmmad1bafbib140
  article-title: Formulation and in vitro evaluation of a siRNA delivery nanosystem decorated with gH625 peptide for triple negative breast cancer theranosis
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/j.ejpb.2018.07.024
  contributor:
    fullname: Ben Djemaa
– volume: 14
  start-page: 2537
  year: 2022
  ident: bmmad1bafbib147
  article-title: Combination of nanovectorized siRNA directed against survivin with doxorubicin for efficient anti-cancer activity in HER2+ breast cancer cells
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics14112537
  contributor:
    fullname: Eljack
– volume: 12
  start-page: 600
  year: 2022
  ident: bmmad1bafbib7
  article-title: Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2021.08.009
  contributor:
    fullname: Zoulikha
– volume: 47
  year: 2011
  ident: bmmad1bafbib60
  article-title: Functional MnO nanoclusters for efficient siRNA delivery
  publication-title: Chem. Commun.
  doi: 10.1039/c1cc15408g
  contributor:
    fullname: Xing
– volume: 5
  start-page: 3431
  year: 2017
  ident: bmmad1bafbib65
  article-title: Gadolinium-based nanoscale MRI contrast agents for tumor imaging
  publication-title: J. Mater. Chem. B
  doi: 10.1039/C7TB00382J
  contributor:
    fullname: Cao
– volume: 12
  start-page: 492
  year: 2010
  ident: bmmad1bafbib104
  article-title: Delivery of siRNA therapeutics: barriers and carriers
  publication-title: AAPS J.
  doi: 10.1208/s12248-010-9210-4
  contributor:
    fullname: Wang
– volume: 4
  start-page: 1
  year: 2009
  ident: bmmad1bafbib67
  article-title: Classification and basic properties of contrast agents for magnetic resonance imaging
  publication-title: Contrast Media Mol. Imaging
  doi: 10.1002/cmmi.265
  contributor:
    fullname: Geraldes
– volume: 5
  start-page: 2673
  year: 2009
  ident: bmmad1bafbib150
  article-title: Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells
  publication-title: Small
  doi: 10.1002/smll.200900621
  contributor:
    fullname: Chen
– start-page: 43
  year: 2007
  ident: bmmad1bafbib5
  article-title: The therapeutic potential of siRNA in gene therapy of neurodegenerative disorders
  doi: 10.1007/978-3-211-73574-9_7
  contributor:
    fullname: Koutsilieri
– volume: 1219
  year: 2020
  ident: bmmad1bafbib81
  article-title: Metallic nanoparticles as x-ray computed tomography (CT) contrast agents: a review
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2020.128599
  contributor:
    fullname: Aslan
– volume: 25
  start-page: 2692
  year: 2020
  ident: bmmad1bafbib26
  article-title: Lipid and polymer-based nanoparticle siRNA delivery systems for cancer therapy
  publication-title: Molecules
  doi: 10.3390/molecules25112692
  contributor:
    fullname: Mainini
– volume: 9
  start-page: 511
  year: 2019
  ident: bmmad1bafbib88
  article-title: Smart mesoporous silica nanoparticles for protein delivery
  publication-title: Nanomaterials
  doi: 10.3390/nano9040511
  contributor:
    fullname: Liu
– volume: 12
  start-page: 5331
  year: 2017
  ident: bmmad1bafbib109
  article-title: Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S137245
  contributor:
    fullname: Luo
– volume: 5
  start-page: 1007
  year: 2022
  ident: bmmad1bafbib161
  article-title: Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: design, development, and clinical studies
  publication-title: ACS Pharmacol. Transl. Sci.
  doi: 10.1021/acsptsci.2c00110
  contributor:
    fullname: Liu
– volume: 35
  start-page: 10058
  year: 2014
  ident: bmmad1bafbib127
  article-title: Highly effective inhibition of lung cancer growth and metastasis by systemic delivery of siRNA via multimodal mesoporous silica-based nanocarrier
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2014.09.003
  contributor:
    fullname: Chen
– volume: 7
  start-page: 1
  year: 2012
  ident: bmmad1bafbib41
  article-title: Stimuli-responsive polymers and their applications in nanomedicine
  publication-title: Biointerphases
  doi: 10.1007/s13758-011-0009-3
  contributor:
    fullname: Cabane
– volume: 7
  start-page: 4784
  year: 2019
  ident: bmmad1bafbib153
  article-title: Development of an interactive tumor vascular suppression strategy to inhibit multidrug resistance and metastasis with pH/H 2 O 2 responsive and oxygen-producing nanohybrids
  publication-title: J. Mater. Chem. B
  doi: 10.1039/C9TB00546C
  contributor:
    fullname: Du
– volume: 9
  year: 2014
  ident: bmmad1bafbib154
  article-title: Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0092924
  contributor:
    fullname: Peng
– volume: 7
  start-page: 32
  year: 2010
  ident: bmmad1bafbib42
  article-title: MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells
  publication-title: Mol. Pharm.
  doi: 10.1021/mp9001393
  contributor:
    fullname: Guthi
– volume: 236
  start-page: 141
  year: 2016
  ident: bmmad1bafbib94
  article-title: Stimuli-responsive mesoporous silica nanoparticles for cancer therapy: a review
  publication-title: Microporous Mesoporous Mater.
  doi: 10.1016/j.micromeso.2016.08.038
  contributor:
    fullname: Moreira
– volume: 221
  year: 2023
  ident: bmmad1bafbib30
  article-title: Current advancements in self-assembling nanocarriers-based siRNA delivery for cancer therapy
  publication-title: Colloids Surf. B
  doi: 10.1016/j.colsurfb.2022.113002
  contributor:
    fullname: Kandasamy
– volume: 30
  year: 2020
  ident: bmmad1bafbib72
  article-title: Optical properties and applications of plasmonic‐metal nanoparticles
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.202005400
  contributor:
    fullname: Wang
– volume: 11
  start-page: 615
  year: 2019
  ident: bmmad1bafbib114
  article-title: Efficient delivery of therapeutic siRNA by Fe3O4 magnetic nanoparticles into oral cancer cells
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics11110615
  contributor:
    fullname: Jin
– volume: 29
  start-page: 7425
  year: 2013
  ident: bmmad1bafbib33
  article-title: Stimuli-responsive magnetic nanomicelles as multifunctional heat and cargo delivery vehicles
  publication-title: Langmuir
  doi: 10.1021/la3044158
  contributor:
    fullname: Kim
– volume: 201
  year: 2023
  ident: bmmad1bafbib106
  article-title: A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2023.115052
  contributor:
    fullname: Ranjbar
– volume: 110
  start-page: 319
  year: 2019
  ident: bmmad1bafbib2
  article-title: Nanosoldiers: a promising strategy to combat triple negative breast cancer
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.11.122
  contributor:
    fullname: Pawar
– volume: 378
  start-page: 40
  year: 2020
  ident: bmmad1bafbib54
  article-title: Magnetic nanoparticles as MRI contrast agents
  publication-title: Top. Curr. Chem.
  doi: 10.1007/s41061-020-00302-w
  contributor:
    fullname: Avasthi
– volume: 13
  start-page: 1169
  year: 2014
  ident: bmmad1bafbib69
  article-title: Gold nanoparticles: synthesis and applications in drug delivery
  publication-title: Trop. J. Pharm. Res.
  doi: 10.4314/tjpr.v13i7.23
  contributor:
    fullname: Khan
– volume: 426
  year: 2021
  ident: bmmad1bafbib144
  article-title: Heat-induced manganese-doped magnetic nanocarriers combined with Yap-siRNA for MRI/NIR-guided mild photothermal and gene therapy of hepatocellular carcinoma
  publication-title: Chem. Eng. J.
  doi: 10.1016/j.cej.2021.130746
  contributor:
    fullname: Zhang
– volume: 99
  start-page: 1182
  year: 2019
  ident: bmmad1bafbib124
  article-title: Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells
  publication-title: Mater. Sci. Eng. C
  doi: 10.1016/j.msec.2019.02.026
  contributor:
    fullname: Dalmina
– volume: 154–155
  start-page: 64
  year: 2020
  ident: bmmad1bafbib25
  article-title: Recent advances in siRNA delivery mediated by lipid-based nanoparticles
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2020.07.022
  contributor:
    fullname: Yonezawa
– volume: 52
  start-page: 1496
  year: 2019
  ident: bmmad1bafbib80
  article-title: Theranostic nanoparticles for RNA-based cancer treatment
  publication-title: Acc. Chem. Res.
  doi: 10.1021/acs.accounts.9b00101
  contributor:
    fullname: Revia
– volume: 20
  start-page: 265
  year: 2021
  ident: bmmad1bafbib130
  article-title: Preparation and preliminary evaluation of dual-functional nanoparticles for MRI and siRNA delivery
  publication-title: Iran. J. Pharm. Res.
  doi: 10.22037/ijpr.2021.115099.15219
  contributor:
    fullname: Sun
– volume: 21
  start-page: 105105
  year: 2010
  ident: bmmad1bafbib82
  article-title: Gold hybrid nanoparticles for targeted phototherapy and cancer imaging
  publication-title: Nanotechnology
  doi: 10.1088/0957-4484/21/10/105105
  contributor:
    fullname: Kirui
– volume: 265
  start-page: 29
  year: 2019
  ident: bmmad1bafbib45
  article-title: Magnetic nanocarriers: evolution of spinel ferrites for medical applications
  publication-title: Adv. Colloid Interface Sci.
  doi: 10.1016/j.cis.2019.01.003
  contributor:
    fullname: Amiri
– volume: 23
  start-page: 14299
  year: 2017
  ident: bmmad1bafbib143
  article-title: MnAl layered double hydroxide nanoparticles as a dual‐functional platform for magnetic resonance imaging and siRNA delivery
  publication-title: Chem. A Eur. J.
  doi: 10.1002/chem.201702835
  contributor:
    fullname: Zuo
– volume: 56
  start-page: 1
  year: 2022
  ident: bmmad1bafbib23
  article-title: Cancer gene therapy goes viral: viral vector platforms come of age
  publication-title: Radiol. Oncol.
  doi: 10.2478/raon-2022-0002
  contributor:
    fullname: Bezeljak
– volume: 16
  start-page: 3069
  year: 2016
  ident: bmmad1bafbib77
  article-title: Gold and silver nanoparticles for applications in theranostics
  publication-title: Curr. Top. Med. Chem.
  doi: 10.2174/1568026616666160715163346
  contributor:
    fullname: Di Pietro
– volume: 8
  start-page: 1
  year: 2020
  ident: bmmad1bafbib85
  article-title: Silica nanoparticles—a versatile tool for the treatment of bacterial infections
  publication-title: Front. Chem.
  doi: 10.3389/fchem.2020.00602
  contributor:
    fullname: Selvarajan
– volume: 10
  start-page: 4557
  year: 2020
  ident: bmmad1bafbib37
  article-title: Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics
  publication-title: Theranostics
  doi: 10.7150/thno.38069
  contributor:
    fullname: Mi
– volume: 47
  start-page: 9972
  year: 2011
  ident: bmmad1bafbib90
  article-title: Mesoporous silica nanoparticles as nanocarriers
  publication-title: Chem. Commun.
  doi: 10.1039/c1cc11760b
  contributor:
    fullname: S-h
– volume: 7
  start-page: 110
  year: 2017
  ident: bmmad1bafbib112
  article-title: Magnetic cationic amylose nanoparticles used to deliver survivin-small interfering RNA for gene therapy of hepatocellular carcinoma in vitro
  publication-title: Nanomaterials
  doi: 10.3390/nano7050110
  contributor:
    fullname: Wu
– volume: 13
  start-page: 294
  year: 2020
  ident: bmmad1bafbib17
  article-title: Overcoming barriers for siRNA therapeutics: from bench to bedside
  publication-title: Pharmaceuticals
  doi: 10.3390/ph13100294
  contributor:
    fullname: Sajid
– volume: 6
  start-page: 11
  year: 2020
  ident: bmmad1bafbib50
  article-title: A review on the optimal design of magnetic nanoparticle-based T2 MRI contrast agents
  publication-title: Magnetochemistry
  doi: 10.3390/magnetochemistry6010011
  contributor:
    fullname: Kostevšek
– volume: 69
  start-page: 279
  year: 2021
  ident: bmmad1bafbib29
  article-title: Nanomedicine in treatment of breast cancer—A challenge to conventional therapy
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2019.12.016
  contributor:
    fullname: Afzal
– volume: 9
  start-page: 6867
  year: 2019
  ident: bmmad1bafbib110
  article-title: A tumor microenvironment responsive biodegradable CaCO3/MnO2—based nanoplatform for the enhanced photodynamic therapy and improved PD-L1 immunotherapy
  publication-title: Theranostics
  doi: 10.7150/thno.37586
  contributor:
    fullname: Liu
– volume: 127
  year: 2021
  ident: bmmad1bafbib10
  article-title: Multifunctional theranostic nanoparticles for biomedical cancer treatments—A comprehensive review
  publication-title: Mater. Sci. Eng. C
  doi: 10.1016/j.msec.2021.112199
  contributor:
    fullname: Kandasamy
– volume: 7
  start-page: 9229
  year: 2015
  ident: bmmad1bafbib123
  article-title: A novel albumin nanocomplex containing both small interfering RNA and gold nanorods for synergetic anticancer therapy
  publication-title: Nanoscale
  doi: 10.1039/C5NR00211G
  contributor:
    fullname: Choi
– volume: 39
  start-page: 125
  year: 2021
  ident: bmmad1bafbib4
  article-title: Atalanta pioneers siRNA for neurodegenerative diseases
  publication-title: Nat. Biotechnol.
  doi: 10.1038/s41587-021-00838-2
– volume: 28
  start-page: 2729
  year: 2017
  ident: bmmad1bafbib142
  article-title: Tuning the multifunctionality of iron oxide nanoparticles using self-assembled mixed lipid layers
  publication-title: Bioconjug. Chem.
  doi: 10.1021/acs.bioconjchem.7b00483
  contributor:
    fullname: Preiss
– volume: 32
  start-page: 9546
  year: 2011
  ident: bmmad1bafbib89
  article-title: The packaging of siRNA within the mesoporous structure of silica nanoparticles
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2011.08.068
  contributor:
    fullname: Li
– volume: 10
  start-page: 321
  year: 2015
  ident: bmmad1bafbib83
  article-title: Gold nanoparticles as contrast agents in x-ray imaging and computed tomography
  publication-title: Nanomedicine
  doi: 10.2217/nnm.14.171
  contributor:
    fullname: Cole
– volume: 13
  start-page: 27806
  year: 2021
  ident: bmmad1bafbib135
  article-title: Low-molecular-weight poly(ethylenimine) nanogels loaded with ultrasmall iron oxide nanoparticles for T 1 -weighted MR imaging-guided gene therapy of sarcoma
  publication-title: ACS Appl. Mater. Interfaces
  doi: 10.1021/acsami.1c04081
  contributor:
    fullname: Peng
– volume: 35
  start-page: 9495
  year: 2014
  ident: bmmad1bafbib136
  article-title: Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2014.07.049
  contributor:
    fullname: Lin
– volume: 2
  start-page: 282
  year: 2010
  ident: bmmad1bafbib68
  article-title: Introduction to metallic nanoparticles
  publication-title: J. Pharm. Bioallied Sci.
  doi: 10.4103/0975-7406.72127
  contributor:
    fullname: Mody
– volume: 13
  start-page: 394
  year: 2021
  ident: bmmad1bafbib138
  article-title: In-vitro application of magnetic hybrid niosomes: targeted siRNA-delivery for enhanced breast cancer therapy
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics13030394
  contributor:
    fullname: Maurer
– volume: 9
  start-page: 191
  year: 2019
  ident: bmmad1bafbib35
  article-title: Clinical trials of thermosensitive nanomaterials: an overview
  publication-title: Nanomaterials
  doi: 10.3390/nano9020191
  contributor:
    fullname: Nardecchia
– volume: 9
  start-page: e1449
  year: 2017
  ident: bmmad1bafbib75
  article-title: Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment
  publication-title: Wiley Interdiscip. Rev.: Nanomed. Nanobiotechnol.
  doi: 10.1002/wnan.1449
  contributor:
    fullname: Riley
– volume: 596
  year: 2021
  ident: bmmad1bafbib28
  article-title: Strategies for cancer gene-delivery improvement by non-viral vectors
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2021.120291
  contributor:
    fullname: Santana-Armas
– volume: 10
  start-page: 503
  year: 2014
  ident: bmmad1bafbib70
  article-title: Gold nanoparticle mediated cancer immunotherapy
  publication-title: Nanomed.: Nanotechnol. Biol. Med.
  doi: 10.1016/j.nano.2013.09.011
  contributor:
    fullname: Almeida
– volume: 80
  start-page: 714
  year: 2019
  ident: bmmad1bafbib8
  article-title: The potential of siRNA based drug delivery in respiratory disorders: recent advances and progress
  publication-title: Drug. Dev. Res.
  doi: 10.1002/ddr.21571
  contributor:
    fullname: Dua
– volume: 125
  year: 2020
  ident: bmmad1bafbib157
  article-title: Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC)
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2019.109561
  contributor:
    fullname: Song
– volume: 234
  start-page: 20554
  year: 2019
  ident: bmmad1bafbib95
  article-title: Carboxymethyl dextran‐trimethyl chitosan coated superparamagnetic iron oxide nanoparticles: an effective siRNA delivery system for HIV‐1 Nef
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.28655
  contributor:
    fullname: Kamalzare
– volume: 14
  start-page: 8321
  year: 2019
  ident: bmmad1bafbib63
  article-title: Manganese oxide nanoparticles as MRI contrast agents in tumor multimodal imaging and therapy
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S218085
  contributor:
    fullname: Cai
– volume: 8
  start-page: 13748
  year: 2016
  ident: bmmad1bafbib151
  article-title: Folate-functionalized magnetic-mesoporous silica nanoparticles for drug/gene codelivery to potentiate the antitumor efficacy
  publication-title: ACS Appl. Mater. Interfaces
  doi: 10.1021/acsami.6b02963
  contributor:
    fullname: Li
– volume: 18
  start-page: 16848
  year: 2016
  ident: bmmad1bafbib62
  article-title: Manganese doped-iron oxide nanoparticle clusters and their potential as agents for magnetic resonance imaging and hyperthermia
  publication-title: Phys. Chem. Chem. Phys.
  doi: 10.1039/C6CP02094A
  contributor:
    fullname: Casula
– volume: 514
  start-page: 534
  year: 2018
  ident: bmmad1bafbib56
  article-title: Systematic magnetic fluid hyperthermia studies of carboxyl functionalized hydrophilic superparamagnetic iron oxide nanoparticles based ferrofluids
  publication-title: J. Colloid. Interface Sci.
  doi: 10.1016/j.jcis.2017.12.064
  contributor:
    fullname: Kandasamy
– volume: 19
  start-page: 900
  year: 2011
  ident: bmmad1bafbib158
  article-title: Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA
  publication-title: J. Drug Target.
  doi: 10.3109/1061186X.2011.622404
  contributor:
    fullname: Taratula
– volume: 119
  start-page: 4819
  year: 2019
  ident: bmmad1bafbib40
  article-title: The role of ligands in the chemical synthesis and applications of inorganic nanoparticles
  publication-title: Chem. Rev.
  doi: 10.1021/acs.chemrev.8b00733
  contributor:
    fullname: Heuer-Jungemann
– volume: 12
  start-page: 6131
  year: 2017
  ident: bmmad1bafbib78
  article-title: Gold nanoparticles enlighten the future of cancer theranostics
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S140772
  contributor:
    fullname: Guo
– start-page: 397
  year: 2011
  ident: bmmad1bafbib66
  article-title: Magnetic and multifunctional magnetic nanoparticles in nanomedicine: challenges and trends in synthesis and surface engineering for diagnostic and therapy applications
  doi: 10.5772/13059
  contributor:
    fullname: Carlos
– volume: 22
  start-page: 7055
  year: 2021
  ident: bmmad1bafbib39
  article-title: Nanocarriers for biomedicine: from lipid formulations to inorganic and hybrid nanoparticles
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms22137055
  contributor:
    fullname: Kashapov
– volume: 15
  start-page: 1
  year: 2019
  ident: bmmad1bafbib107
  article-title: Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review
  publication-title: J. Adv. Res.
  doi: 10.1016/j.jare.2018.06.005
  contributor:
    fullname: Hossen
– volume: 3
  start-page: 1948
  year: 2020
  ident: bmmad1bafbib32
  article-title: Nanomaterials for therapeutic RNA delivery
  publication-title: Matter
  doi: 10.1016/j.matt.2020.09.020
  contributor:
    fullname: Han
– volume: 12
  start-page: 87
  year: 2016
  ident: bmmad1bafbib86
  article-title: Mesoporous silica nanoparticles for stimuli-responsive controlled drug delivery: advances, challenges, and outlook
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S117495
  contributor:
    fullname: Song
– volume: 24
  start-page: 247
  year: 2016
  ident: bmmad1bafbib119
  article-title: Magnetic albumin immuno-nanospheres as an efficient gene delivery system for a potential use in lung cancer: preparation, in vitro targeting and biological effect analysis
  publication-title: J. Drug Target.
  doi: 10.3109/1061186X.2015.1070857
  contributor:
    fullname: Hou
– volume: 144
  start-page: 133
  year: 2019
  ident: bmmad1bafbib15
  article-title: Strategies, design, and chemistry in siRNA delivery systems
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2019.05.004
  contributor:
    fullname: Dong
– volume: 293
  year: 2019
  ident: bmmad1bafbib55
  article-title: Multifunctional magnetic-polymeric nanoparticles based ferrofluids for multi-modal in vitro cancer treatment using thermotherapy and chemotherapy
  publication-title: J. Mol. Liq.
  doi: 10.1016/j.molliq.2019.111549
  contributor:
    fullname: Kandasamy
– year: 2019
  ident: bmmad1bafbib48
  doi: 10.1007/978-3-030-29768-8_12
  contributor:
    fullname: Maity
– volume: 99
  start-page: 307
  year: 2019
  ident: bmmad1bafbib111
  article-title: Effects of gold nanoprism-assisted human PD-L1 siRNA on both gene down-regulation and photothermal therapy on lung cancer
  publication-title: Acta Biomater.
  doi: 10.1016/j.actbio.2019.08.046
  contributor:
    fullname: Liu
– volume: 313
  start-page: 80
  year: 2019
  ident: bmmad1bafbib14
  article-title: MicroRNA delivery through nanoparticles
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2019.10.007
  contributor:
    fullname: Lee
– volume: 214
  start-page: 62
  year: 2019
  ident: bmmad1bafbib103
  article-title: Efficient nanocarriers of siRNA therapeutics for cancer treatment
  publication-title: Transl. Res.
  doi: 10.1016/j.trsl.2019.07.006
  contributor:
    fullname: Subhan
– volume: 10
  year: 2018
  ident: bmmad1bafbib34
  article-title: Beyond traditional hyperthermia. In vivo cancer treatment with magnetic-responsive mesoporous silica nanocarriers
  publication-title: ACS Appl. Mater. Interfaces
  doi: 10.1021/acsami.8b02398
  contributor:
    fullname: Guisasola
– volume: 3
  start-page: 3279
  year: 2011
  ident: bmmad1bafbib1
  article-title: Assessment of the evolution of cancer treatment therapies
  publication-title: Cancers
  doi: 10.3390/cancers3033279
  contributor:
    fullname: Arruebo
– volume: 146
  start-page: 188
  year: 2016
  ident: bmmad1bafbib145
  article-title: Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma
  publication-title: Colloids Surf. B
  doi: 10.1016/j.colsurfb.2016.05.076
  contributor:
    fullname: Labala
– volume: 511
  start-page: 101
  year: 2018
  ident: bmmad1bafbib52
  article-title: Magnetic hyperthermia efficiency and MRI contrast sensitivity of colloidal soft/hard ferrite nanoclusters
  publication-title: J. Colloid. Interface Sci.
  doi: 10.1016/j.jcis.2017.10.001
  contributor:
    fullname: Vamvakidis
– volume: 109
  year: 2020
  ident: bmmad1bafbib139
  article-title: Multifunctional hybrid nanoparticles as magnetic delivery systems for siRNA targeting the HER2 gene in breast cancer cells
  publication-title: Mater. Sci. Eng. C
  doi: 10.1016/j.msec.2019.110555
  contributor:
    fullname: Cristofolini
– volume: 156
  start-page: 188
  year: 2020
  ident: bmmad1bafbib31
  article-title: Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2020.06.020
  contributor:
    fullname: Luther
– volume: 4
  start-page: 574
  year: 2020
  ident: bmmad1bafbib146
  article-title: Active targeting co-delivery of therapeutic Sur siRNA and an antineoplastic drug via epidermal growth factor receptor-mediated magnetic nanoparticles for synergistic programmed cell death in glioblastoma stem cells
  publication-title: Mater. Chem. Front.
  doi: 10.1039/C9QM00666D
  contributor:
    fullname: Wang
– volume: 31
  start-page: 4971
  year: 2019
  ident: bmmad1bafbib38
  article-title: Externally addressable smart drug delivery vehicles: current technologies and future directions
  publication-title: Chem. Mater.
  doi: 10.1021/acs.chemmater.9b01798
  contributor:
    fullname: Said
– volume: 483
  start-page: 1069
  year: 2019
  ident: bmmad1bafbib141
  article-title: Facile synthesis and direct characterization of surface-charge-controlled magnetic iron oxide nanoparticles and their role in gene transfection in human leukemic T cell
  publication-title: Appl. Surf. Sci.
  doi: 10.1016/j.apsusc.2019.04.059
  contributor:
    fullname: H-k
– volume: 19
  start-page: 1896
  year: 2021
  ident: bmmad1bafbib3
  article-title: siRNA therapeutics: future promise for neurodegenerative diseases
  publication-title: Curr. Neuropharmacol.
  doi: 10.2174/1570159X19666210402104054
  contributor:
    fullname: Amiri
– volume: 20
  start-page: 5491
  year: 2019
  ident: bmmad1bafbib27
  article-title: The development of functional non-viral vectors for gene delivery
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20215491
  contributor:
    fullname: Patil
– volume: 14
  start-page: 767
  year: 2019
  ident: bmmad1bafbib74
  article-title: Gold nanostructures as cancer theranostic probe: promises and hurdles
  publication-title: Nanomedicine
  doi: 10.2217/nnm-2018-0170
  contributor:
    fullname: Navyatha
– volume: 12
  start-page: 1692
  year: 2022
  ident: bmmad1bafbib131
  article-title: Fluorinated PEG-PEI coated magnetic nanoparticles for siRNA delivery and CXCR4 knockdown
  publication-title: Nanomaterials
  doi: 10.3390/nano12101692
  contributor:
    fullname: Cao
– volume: 5
  start-page: 101569
  year: 2015
  ident: bmmad1bafbib117
  article-title: Polyethylenimine mediated magnetic nanoparticles for combined intracellular imaging, siRNA delivery and anti-tumor therapy
  publication-title: RSC Adv.
  doi: 10.1039/C5RA18464A
  contributor:
    fullname: Wang
– volume: 156
  start-page: 84
  year: 2020
  ident: bmmad1bafbib156
  article-title: Targeted rod-shaped mesoporous silica nanoparticles for the co-delivery of camptothecin and survivin shRNA in to colon adenocarcinoma in vitro and in vivo
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/j.ejpb.2020.08.026
  contributor:
    fullname: Babaei
– volume: 142
  start-page: 145
  year: 2017
  ident: bmmad1bafbib116
  article-title: Apoptosis induction activity and molecular docking studies of survivin siRNA carried by Fe3O4-PEG-LAC-chitosan-PEI nanoparticles in MCF-7 human breast cancer cells
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2017.04.025
  contributor:
    fullname: Arami
– volume: 48
  year: 2012
  ident: bmmad1bafbib53
  article-title: Surface design of core–shell superparamagnetic iron oxide nanoparticles drives record relaxivity values in functional MRI contrast agents
  publication-title: Chem. Commun.
  doi: 10.1039/c2cc35515a
  contributor:
    fullname: Maity
– volume: 30
  year: 2020
  ident: bmmad1bafbib93
  article-title: Mesoporous silica nanoparticles for drug delivery
  publication-title: Adv. Funct. Mater.
  doi: 10.1002/adfm.201902634
  contributor:
    fullname: Manzano
– volume: 15
  start-page: 220
  year: 2020
  ident: bmmad1bafbib100
  article-title: Research and development of drug delivery systems based on drug transporter and nano-formulation
  publication-title: Asian J. Pharm. Sci.
  doi: 10.1016/j.ajps.2020.02.004
  contributor:
    fullname: Peng
– volume: 3
  start-page: 3991
  year: 2018
  ident: bmmad1bafbib57
  article-title: Functionalized hydrophilic superparamagnetic iron oxide nanoparticles for magnetic fluid hyperthermia application in liver cancer treatment
  publication-title: ACS Omega
  doi: 10.1021/acsomega.8b00207
  contributor:
    fullname: Kandasamy
– volume: 142
  start-page: 101
  year: 2017
  ident: bmmad1bafbib122
  article-title: Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2017.07.024
  contributor:
    fullname: Guruprasath
– volume: 128
  start-page: 82
  year: 2018
  ident: bmmad1bafbib44
  article-title: Non-viral based miR delivery and recent developments
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/j.ejpb.2018.04.018
  contributor:
    fullname: Labatut
SSID ssj0059539
Score 2.4114273
SecondaryResourceType review_article
Snippet RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method specifically uses...
Abstract RNA interference is one of the emerging methodologies utilized in the treatment of a wide variety of diseases including cancer. This method...
SourceID proquest
crossref
pubmed
iop
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 22001
SubjectTerms Bcl-2 and VEGF
cancer treatment
chemotherapy
Drug Carriers
Drug Delivery Systems - methods
Humans
magnetic/metal/silica nanoparticles
Nanoparticles
Neoplasms - drug therapy
PD-L1
RNA, Small Interfering - genetics
siRNA
survivin
Vascular Endothelial Growth Factor A
Title Inorganic nanocarriers for siRNA delivery for cancer treatments
URI https://iopscience.iop.org/article/10.1088/1748-605X/ad1baf
https://www.ncbi.nlm.nih.gov/pubmed/38181441
https://search.proquest.com/docview/2915572255
Volume 19
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEB5cvejB92N9UUEPHrrb5tEHHkREUcEHorAHIaRpAqJ2l-3uQX-9k6a7qKiIpz4Y0ukkM_MNmcwA7FKecZkq7bM4YBigxMzHp8DnSI7ukJigOsd9eRWd3bOLDu9MwMH4LEy3V5v-Ft66QsFOhHVCXNJGDJ34iMI7bZmHmTQNmKKoKjbyOr--GZlhnvKqjVhNzcJ6j_K7ET75pAZ-92e4Wbmd0zl4GDHssk2eWsNB1lJvX2o5_vOP5mG2hqPekSNdgAldLMLMhyKFS3B4XrjWT8orZIGur2-b3JUeol2vfLy9OvJy_WyzO16rV8ouo743TmAvl-Hu9OTu-Myv2y74ikZ04LOURQlRcWzS1DCm0YtqyYPQaJrTSOHVKJqG0pAcY2uT2vI-kVSUK86o1nQFJotuodfAY2GGAyRKRqFkkSGZyROLH4wkQUYVacL-SO6i54priGpTPEmElYmwMhFOJk3YQ_GJWsPKX-i8T3TZy4sIU0GEPVIchKKXI8nOaHYFKpPdIZGF7g5LQWy1_BhNHG_Cqpv2MWMW2tjoc_2PjGzANEEA5PLVNmFy0B_qLQQwg2y7Wqjvk-Xp1A
link.rule.ids 315,783,787,27936,27937,38877,53854
linkProvider IOP Publishing
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9tAEB6VIFVwKLRACVDqSuXAwYm9Dz9OCNFGCY8UIZByW9brXakCnChODvTXM-t1ooIAIXHyQ2N7_e1jvtXOfgPwk_KMy1Rpn8UBwwlKzHy8CnyO5ugOiQmqfdxn_ah7xY4HfFDnOa32wgxH9dDfwlMnFOwgrAPikjZy6MRHFj5oyzzMpGmPcrMAi9hzuRXP7_05nw3FPOVVKrH6CRbW65TPveWRX1rAb79MOSvX01mB61mhXcTJTWs6yVrq3xM9x3f81Sp8qmmpd-jMP8MHXXyB5f_ECtfgoFe4FFDKK2SBLnBsk92VHrJer_x70T_0cn1rozzuq1vKNqexNw9kL9fhsvP78qjr1-kXfEUjOvFZyqKEqDg2aWoY0-hNteRBaDTNaaTwaBRNQ2lIjnNsk1qZn0gqyhVnVGu6AY1iWOhN8FiY4QsSJaNQssiQzOSJ5RFGkiCjijRhf4a9GDmRDVEtjieJsLgIi4twuDRhDyEUdU8rX7HzHtlld3ciTAURdmtxEAqEtwk_ZjUssFPZlRJZ6OG0FMSq5sc41PEmfHVVPy-YpTh2Frr1xoJ8h4_nvzritNc_2YYlgpzIhbDtQGMynupvyGkm2W7Vbh8APejvNA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inorganic+nanocarriers+for+siRNA+delivery+for+cancer+treatments&rft.jtitle=Biomedical+materials+%28Bristol%29&rft.au=Kandasamy%2C+Ganeshlenin&rft.au=Maity%2C+Dipak&rft.date=2024-03-01&rft.pub=IOP+Publishing&rft.issn=1748-6041&rft.eissn=1748-605X&rft.volume=19&rft.issue=2&rft_id=info:doi/10.1088%2F1748-605X%2Fad1baf&rft.externalDocID=bmmad1baf
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1748-6041&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1748-6041&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1748-6041&client=summon